Essa Pharma (EPIX)

Dec 17, 2024, 7:00 AM EST - 4 weeks ago

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2024

Nov 6, 2024, 10:00 AM EST - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ESSA Pharma Inc. (EPIX) and Encourages Shareholders to Learn More About the Investigation

Nov 5, 2024, 10:00 AM EST - 2 months ago

ESSA Pharma Inc. (EPIX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Nov 4, 2024, 10:00 AM EST - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating ESSA Pharma Inc. (EPIX) And Encourages Investors to Connect

Nov 3, 2024, 10:00 AM EST - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating ESSA Pharma Inc. (EPIX) And Encourages Stockholders to Connect

Nov 1, 2024, 5:00 PM EDT - 2 months ago

ESSA Pharma Inc. (EPIX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Oct 31, 2024, 8:57 PM EDT - 2 months ago

ESSA Pharma Announces Termination of Phase 2 Study Evaluating Masofaniten Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer

Sep 13, 2024, 5:19 PM EDT - 4 months ago

ESSA Pharma Presents Updated Phase 1/2 Masofaniten (EPI-7386) Clinical Data at the 2024 ESMO Congress

Sep 11, 2024, 4:05 PM EDT - 4 months ago

ESSA Pharma to Present at the 2024 Cantor Global Healthcare Conference

Aug 5, 2024, 7:00 AM EDT - 5 months ago

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2024

Jul 8, 2024, 4:05 PM EDT - 6 months ago

ESSA Pharma to Present at the JonesHealthcare Seaside Summit

May 30, 2024, 8:00 AM EDT - 8 months ago

ESSA Pharma to Present at the Jefferies Global Healthcare Conference

May 29, 2024, 5:44 PM EDT - 8 months ago

ESSA Pharma's Speculative Buy Potential: Masofaniten Promise For Prostate Cancer

May 14, 2024, 7:00 AM EDT - 8 months ago

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2024

Apr 9, 2024, 8:00 AM EDT - 10 months ago

ESSA Pharma to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

Mar 7, 2024, 8:13 PM EST - 11 months ago

ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS

Feb 13, 2024, 7:00 AM EST - 1 year ago

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2023

Feb 6, 2024, 8:00 AM EST - 1 year ago

ESSA Pharma to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Jan 25, 2024, 10:00 AM EST - 1 year ago

ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 2024 ASCO Genitourinary Cancers Symposium

Dec 12, 2023, 7:00 AM EST - 1 year ago

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2023

Nov 21, 2023, 8:00 AM EST - 1 year ago

ESSA Pharma to Present at the Piper Sandler 35th Annual Healthcare Conference

Nov 8, 2023, 8:00 AM EST - 1 year ago

ESSA Pharma to Present at the Jefferies London Healthcare Conference

Nov 7, 2023, 7:06 PM EST - 1 year ago

ESSA Pharma: Unique N-Terminal Domain Approach Might Hinder mCRPC Resistance

Nov 6, 2023, 5:51 PM EST - 1 year ago

ESSA Pharma Enters into At-The-Market Equity Offering Sales Agreement

Sep 18, 2023, 7:00 AM EDT - 1 year ago

ESSA Pharma Announces Initiation of Phase 2 Study Evaluating Masofaniten (EPI-7386) in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer

Aug 31, 2023, 7:00 AM EDT - 1 year ago

ESSA Pharma Insiders Establish Automatic Securities Disposition Plans

Aug 8, 2023, 7:00 AM EDT - 1 year ago

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2023

Jun 6, 2023, 7:00 AM EDT - 1 year ago

ESSA Pharma Appoints Lauren Merendino to its Board of Directors

Jun 1, 2023, 7:00 AM EDT - 1 year ago

ESSA Pharma to Present at 2023 Jefferies Healthcare Conference

May 11, 2023, 7:00 AM EDT - 1 year ago

ESSA Pharma to Present at JMP Securities Life Sciences Conference

May 9, 2023, 7:00 AM EDT - 1 year ago

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2023

Apr 12, 2023, 7:00 AM EDT - 1 year ago

ESSA Pharma Announces Clinical Trial Support Agreement with Janssen to Evaluate EPI-7386 Combinations in Patients with Prostate Cancer

Mar 8, 2023, 7:00 AM EST - 2 years ago

ESSA Pharma to Present at the Oppenheimer 33rd Annual Healthcare Conference

Feb 13, 2023, 5:00 PM EST - 2 years ago

ESSA Pharma Announces Presentations at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU)

Feb 7, 2023, 7:00 AM EST - 2 years ago

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2022

Feb 6, 2023, 8:28 AM EST - 2 years ago

ESSA Pharma: One Asset, One Program Company With Little Data

Feb 2, 2023, 4:01 PM EST - 2 years ago

ESSA Pharma to Participate in the Guggenheim Healthcare Talks 5th Annual Oncology Conference

Dec 13, 2022, 7:00 AM EST - 2 years ago

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2022

Nov 15, 2022, 10:01 PM EST - 2 years ago

ESSA Pharma: EPI-7386+Xtandi Combination Has Shown Highest Efficacy In Metastatic, Castration-Resistant Prostate Cancer

Nov 10, 2022, 7:00 AM EST - 2 years ago

ESSA Pharma to Participate in Two Upcoming Investor Conferences

Oct 31, 2022, 8:58 AM EDT - 2 years ago

J&J suspends enrollment in clinical trial assessing Essa Pharma's prostate cancer treatment

JNJ